Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
McKinsey
Mallinckrodt
Merck
Boehringer Ingelheim

Last Updated: May 26, 2022

NEURACEQ Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Neuraceq patents expire, and what generic alternatives are available?

Neuraceq is a drug marketed by Life Molecular and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-four patent family members in twenty-six countries.

The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this compound. Additional details are available on the florbetaben f-18 profile page.

DrugPatentWatch® Generic Entry Outlook for Neuraceq

Neuraceq was eligible for patent challenges on March 21, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 18, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for NEURACEQ
International Patents:34
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 3
Clinical Trials: 6
Patent Applications: 101
What excipients (inactive ingredients) are in NEURACEQ?NEURACEQ excipients list
DailyMed Link:NEURACEQ at DailyMed
Drug patent expirations by year for NEURACEQ
DrugPatentWatch® Estimated Generic Entry Opportunity Date for NEURACEQ
Generic Entry Date for NEURACEQ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NEURACEQ

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Life Molecular Imaging GmbHPhase 3
William Charles KreislPhase 1/Phase 2
Ulsan University HospitalN/A

See all NEURACEQ clinical trials

US Patents and Regulatory Information for NEURACEQ

NEURACEQ is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of NEURACEQ is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting NEURACEQ

Stilbene derivatives and their use for binding and imaging amyloid plaques
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Life Molecular NEURACEQ florbetaben f-18 SOLUTION;INTRAVENOUS 204677-001 Mar 19, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NEURACEQ

When does loss-of-exclusivity occur for NEURACEQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 05316421
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 0516408
Estimated Expiration: See Plans and Pricing

Canada

Patent: 91534
Estimated Expiration: See Plans and Pricing

China

Patent: 1123995
Estimated Expiration: See Plans and Pricing

Costa Rica

Patent: 06
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 13652
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 2334
Estimated Expiration: See Plans and Pricing

Patent: 0701299
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 38298
Estimated Expiration: See Plans and Pricing

Patent: 41465
Estimated Expiration: See Plans and Pricing

Patent: 13652
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 500014
Estimated Expiration: See Plans and Pricing

Israel

Patent: 3946
Estimated Expiration: See Plans and Pricing

Patent: 6091
Estimated Expiration: See Plans and Pricing

Japan

Patent: 28956
Estimated Expiration: See Plans and Pricing

Patent: 08524243
Estimated Expiration: See Plans and Pricing

Lithuania

Patent: 213652
Estimated Expiration: See Plans and Pricing

Luxembourg

Patent: 647
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 07007380
Estimated Expiration: See Plans and Pricing

Netherlands

Patent: 0719
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 5942
Estimated Expiration: See Plans and Pricing

Norway

Patent: 9195
Estimated Expiration: See Plans and Pricing

Patent: 073650
Estimated Expiration: See Plans and Pricing

Poland

Patent: 13652
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 13652
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 4363
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 13652
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 0705104
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1321619
Estimated Expiration: See Plans and Pricing

Patent: 070093427
Estimated Expiration: See Plans and Pricing

Spain

Patent: 26655
Estimated Expiration: See Plans and Pricing

Ukraine

Patent: 996
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NEURACEQ around the world.

Country Patent Number Title Estimated Expiration
South Korea 101321619 See Plans and Pricing
European Patent Office 2213652 Dérivés de stilbène et leur utilisation pour l'imagerie des plaques amyloïdes et leur liaison (Stilbene derivatives and their use for binding and imaging amyloid plaques) See Plans and Pricing
Japan 5128956 See Plans and Pricing
Hungary S1500014 See Plans and Pricing
Japan 4950031 See Plans and Pricing
Netherlands 300719 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NEURACEQ

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2213652 SPC/GB15/010 United Kingdom See Plans and Pricing PRODUCT NAME: FLORBETABEN (18F), WHICH IS (4-((E)-2-(4-(2-(2-(2-(1F)FLUOROETHOXY)ETHOXY)ETHOXY)PHENYL)ETHENYL)-N-METHYLANILINE); REGISTERED: UK EU/1/13/906/001 20140224
2213652 PA2015005 Lithuania See Plans and Pricing PRODUCT NAME: FLORBETABENUM (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140220
2213652 132015902339134 Italy See Plans and Pricing PRODUCT NAME: FLORBETABEN (18)(NEURACEQ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/906, 20140224
2213652 C02213652/01 Switzerland See Plans and Pricing PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66210 23.08.2017
2213652 8/2015 Austria See Plans and Pricing PRODUCT NAME: FLORBETABEN (18 F); REGISTRATION NO/DATE: EU/1/13/906/001 (MITTEILUNG) 20140224
2213652 92647 Luxembourg See Plans and Pricing PRODUCT NAME: FLORBETABEN (18F). FIRST REGISTRATION: 20140224
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Johnson and Johnson
Colorcon
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.